Smoke-free environments in mental health and substance use treatment organizations can reduce tobacco use among these individuals and improve the health of the staff, and yet many mental health and ...
In the U.S., 34% of adults with mental health challenges who use tobacco identify as Black, and 32% identify as Hispanic/Latinx. Understanding this relationship between mental health and substance use ...
Description On February 10, 2022, the U.S. Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) is holding a public webinar titled “FDA’s Rulemaking Process and Planned Tobacco Product ...
Varenicline, an FDA-approved prescription smoking cessation aid, is an effective evidence-based treatment for reducing tobacco use among individuals with mental health and substance use challenges. Join the National Behavioral Health ...
National, state, and local-level data sources are essential to address tobacco-related disparities among individuals with mental health and substance use challenges. But, knowing how to find, understand and apply these ...
Tobacco Use Disorder Integration Office Hours - Monthly Learning Cohort Series Seeking to strengthen partnerships and collaborations with mental health and substance use treatment systems and providers to address tobacco-related ...
Call-on Congress Date: March 16 - March 17 Where: National Mall (D.C., Washington) FIGHT COLORECTAL CANCER IS hosting the first-ever colorectal cancer awareness installation on the National Mall and meeting ...
Individuals with mental health and substance use challenges have lower-than-average cancer screening rates and are at greater risk of developing colorectal cancer than the general population. Integrating conversations around mental ...
